Novo Nordisk Forecasts Sales Slowdown from Generic Competition

Company Acknowledges Market Impact

The Danish pharmaceutical giant made the statement in February 2026, marking the first time the company has officially acknowledged the business impact of Canada's unique position as the only country where semaglutide patents have expired. Health Canada is currently reviewing nine generic semaglutide applications from various manufacturers.

Generic Timeline and Pricing

Multiple generic manufacturers are targeting regulatory approval between May and September 2026, with some companies already beginning production in Canadian facilities. Industry analysts expect generic versions to be priced at approximately 35% of current brand-name costs, which currently range from $400 to $570 CAD monthly for Wegovy.

Aspen Pharmacare is among the companies targeting regulatory approval in Canada between May and September for its generic semaglutide product. Other manufacturers including Sandoz, Teva, and Vimy Pharma have also submitted applications to Health Canada.

Market Size and Competition

According to IQVIA Canada data, total 2025 semaglutide sales in Canada reached approximately $3.5 billion, including both Ozempic and Wegovy. This substantial market has attracted significant interest from generic manufacturers seeking to capitalize on the patent expiration.

Vimy Pharma, a Canadian company, expects to file its application for generic semaglutide to Health Canada in the coming weeks, joining eight other applications already under review. The company aims to position itself as a domestic alternative to international generic suppliers.

Regulatory Status

Health Canada's review process for generic semaglutide applications continues, with the regulator maintaining its standard approval timeline. The patent for semaglutide medications expired on January 4, 2026, clearing the regulatory pathway for generic competition.

Patients interested in tracking generic availability can use our generic semaglutide tracker for updates on Health Canada approvals and market launches. Our insurance coverage checker can help determine current coverage options for both brand-name and generic versions.

Industry Implications

Novo Nordisk's acknowledgment of sales impact reflects the significant market disruption expected from generic competition. The company has already announced price reductions of up to 50% for Ozempic and Wegovy beginning in 2027, indicating preparation for increased competition.

Canada's position as the first country with expired semaglutide patents has attracted international attention, with some manufacturers viewing the Canadian market as a testing ground for global generic launches. For more information about the regulatory process, visit our FAQ section.